3R-( + )-cis-4-Methyl-HA966 (L-687,414) is a novel and selective, low intrinsic activity, partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor. Thus, while it acts primarily to block NMDA receptor function in the presence of glycine, it fails to produce a complete block of NMDA receptor activation. In this study, we have investigated its neuroprotective effects in a rat model of focal ischaemia, involving per manent occlusion of the left middle cerebral artery. L-687,414 was administered as a bolus dose of 17. 6 mg/kg i. v. straight after the occlusion or as a bolus dose + in fusion for 4 h. The doses of L-687,414 used for the infu sion studies were 7 mg/kg i.v. + 7 mg/kg/h, 14 mg/kg + 14 mg/kg/h, or 30 mg/kg + 30 mg/kg/h. The 17. 6-mg/kg dose gave an estimated peak plasma level of 24 f.lg/ml, which decayed with a t1/2 of 56 min. The three infusion dosing regimens gave mean plasma levels over the 4 h of 11, 25, and 61 f.lg/ml plasma, respectively. The 17.6-mg/kg dose of L-687,414 gave no significant protection against the volume of hemispheric, cortical, or caudate damage when compared with the control group of animals. The lowest infusion dosing regimen of L-687,414 which gave a plasma level of 11 f.lg/ml over the 4 h was also ineffective
The role of excitatory amino acids in mediating ischaemia-induced neuronal degeneration is now widely accepted (for a review see . It has been shown that excitatory amino ac ids increase severalfold following periods of tran sient forebrain (Benveniste et al. , 1984; Hagberg et against the volume of infarction measured in the different brain regions. The middle dose of L-687,414 (25 f.lg/ml) gave a highly significant reduction in the volume of isch aemic brain damage for the hemisphere and cerebral cor tex, volumes of ischaemic tissue being reduced by 34 and 41 % compared with saline-treated animals, respectively. The highest plasma concentration of L-687 ,414 (61 f.lg/ml) resulted in a 18% reduction in the volume of hemispheric damage and a 21% reduction in the volume of cortical damage, which were significant. The reduced protection afforded by the highest dose of L-687,414 may be due to the slight hypotensive (MABP decreased by 13-16 mm Hg) effect produced by this dose. There was no protec tion seen against the volume of damage in the caudate nucleus for any of the doses of L-687,414 tested. Thus, L-687,414 was effective in producing neuroprotection in this model of ischaemia at doses that do not affect MABP or have any other of the adverse effects associated with neuroprotective doses of NMDA receptor ion channel blockers such as MK-801. Key Words: Cerebral isch aemia-Excitatory amino acids-Glutamate-Glycine N-Methyl-D-aspartate. al. , 1985) and focal (Hillered et al., 1989; Butcher et al. , 1990) ischaemia. The N-methyl-o-aspartate (NMDA) subtype of glutamate receptors appears to play a particularly important role in mediating the ischaemic neuronal degeneration. There is a high density of these receptors in areas that are vulner able to ischaemic damage, and an important prop erty of the NMDA receptor is that it is permeable to calcium (MacDermott et al. , 1986) . High intracellu lar levels of calcium that occur following ischaemia are considered to be the trigger for cell death (Siesjo, 1981) .
Substantial evidence now exists showing the neu roprotective actions of NMDA antagonists in focal ischaemia models (e.g., Park et al., 1988 Park et al., , 1992 Bul lock et al., 1990; Gill et al., 1991a) . The most potent and effective of these compounds studied so far in focal ischaemia models have been noncompetitive antagonists acting at the ion channel site, e.g., MK-80 1 (e.g., Park et al., 1988; Gill et al., 1991a) . How ever, at neuroprotective doses, these compounds have a number of additional actions, including car diovascular effects, increases in glucose utilisation, and production of neuronal vacuoles in certain brain regions, which may compromise their clinical development (McCulloch and Iversen, 1991) . In an attempt to alleviate some of these unwanted effects whilst maintaining neuroprotective efficacy, we de veloped L-687,414, the 3R-( + )-cis-4-methyl ana logue of HA966, which is a selective, low intrinsic activity, partial agonist at the glycine site on the NMDA receptor that readily penetrates the brain following systemic administration (Kemp et al., 199 1; Saywell et al., 1991) . We argued that, due to its low intrinsic activity, L-687 ,4 14 would act to an tagonise the NMDA receptor overactivation that occurs during an ischaemic event, but, at the same time, because it produces a graded and incomplete block of NMDA receptors, would lack the adverse effects seen with noncompetitive NMDA receptor blockade.
Therefore, we have investigated the neuroprotec tive actions of L-687,4 14 in a rat middle cerebral artery (MCA) occlusion model of focal cerebral ischaemia. This work has previously been pre sented as an abstract (Gill et al., 1991b) .
METHODS

Surgical procedures
Male Sprague-Dawley rats weighing 350-380 g were used for these studies. They were maintained on a 12-h light/dark cycle and fed ad libitum.
The rats were anaesthetised with a mixture of 3% halo thane in 30% oxygen and 70% nitrous oxide, a tracheot omy was performed, and the animals were ventilated with a mixture of 2% halothane in 30% oxygen and 70% nitrous oxide. The left femoral artery and vein were cannulated to enable continuous monitoring of blood pressure, blood sampling, and injections. All relevant physiological vari ables were monitored throughout the study. The rats were then subjected to permanent occlusion of the left MCA as described by Tamura et al. (1981) and Shigeno et al. (1985) . Briefly, the temporalis muscle was divided and a craniectomy was performed near the foramen ovale; the zygomatic arch was not removed. The left MCA was lo cated and then coagulated using micro bipolar coagula tion. It was permanently occluded from its stem to the lenticulostriate branch. It was then cut to make sure it had been successfully occluded. The retracted temporalis muscle was allowed to fall back into place and sutured, as was the skin overlying it, and the animals were ventilated with a mixture of 0. 5% halothane in 30% oxygen and 70% J Cereb Blood Flow Metab, Vol. 15, No.2, 1995 nitrous oxide for the remainder of the experiment. The animals were allowed to survive for a period of 4 h, and during this time the blood pressure, blood pH, glucose levels, P aC02, and P a02 were continuously monitored. The core body temperature was maintained at 37 ± 0.8°C throughout the experiment using a rectal probe and ther mostatically controlled heating blanket (Harvard, U. K. ). The temporalis muscle temperature was maintained at 37 ± 0. 8°C using a needle thermistor probe and overhead lamp.
Perfusion and fixation
Following the 4-h experimental period, the animals were deeply anaesthetised by increasing the halothane to 3% in 30% oxygen and 70% nitrous oxide. They were perfused transcardially with 0.9% heparinised saline at 100 mm Hg until the perfusate from the right atrium ran clear. The animals were then perfused with 200 ml of a mixture of 40% formaldehyde, glacial acetic acid, and methanol (1: 1 :8, by vol) (Brown and Brierley, 1968) at 100 mm Hg. The brains were removed after 24 h, processed, and embedded in paraffin wax, and 8-f.Lm coronal sections were stained with haematoxylin-eosin. These sections were examined by light microscopy, and areas of isch aemic damage were delineated at eight preselected coro nal levels from anterior 10. 5 mm to anterior 1.0 mm (Konig and Klippel, 1963) . This was done blind to the treatment of the animals.
Quantification of ischaemic damage
The areas of ischaemic brain damage were transposed onto scale diagrams (4 x actual size of the brain) of fore brain and measured in terms of hemispheric, cortical, and caudate damage using an image analyser (Quantimet 760; Cambridge Instruments). The areas of ischaemic damage were used to determine the total volume of ischaemic tissue in each brain (Osborne et aI. , 1987) by integration of areas with the distance between each level.
Experimental groups
L-687,414 was studied at four different dosing regi mens. In the first experiment, 17.6 mg/kg i. v. of L-687 ,414 (n = 10) was administered immediately follow ing the MCA occlusion. The animals were allowed to sur vive for 4 h, and blood samples were taken at 30 min, 1, 2, 3, and 4 h after the drug had been administered. These samples were analysed to evaluate the plasma levels of the compound. In the second experiment, L-687,414 was administered at a dose of 7 mg/kg i. v. followed by an infusion of 7 mg/kg/h (n = 13) for 4 h. The bolus dose and infusion were administered straight after the occlusion. The third experiment involved giving an intravenous bo lus dose of 14 mg/kg straight after the occlusion followed by an infusion of 14 mg/kg/h (n = 11) for 4 h. In the final experiment an intravenous bolus dose of 30 mg/kg was administered followed by an infusion of 30 mg/kg/h (n = 16) for 4 h. In the infusion experiments, blood samples were taken at 1, 2, 3, and 4 h postocclusion for drug plasma level analysis. All of the doses are quoted as free base of compound. In each of the experiments, there was a control group that received an intravenous bolus dose of saline followed by an infusion of saline of 1.11 m U h (Razel pump). The numbers of animals in the control groups varied from n = 10 to n = 16. The plasma samples were analysed using an HPLC assay and values of L-687,414 in plasma were calculated in terms of free base in micro grams per milliliter.
Statistical analysis
The differences in the volume of ischaemic damage for each brain region (hemisphere, cortex, and caudate) for the control and L-687 ,414-treated animals were evaluated using analysis of variance (ANOVA) with a Bonferroni correction. The area of ischaemic damage at the different stereotactic levels was compared for the control and L-687,414-treated groups using BMDP 2v (BMDP Statis tical Software, Ireland) with repeated measures. This was followed by a comparison of the area of damage at each coronal plane for the two groups using the BMDP con trast test. All data are presented as means ± SD for n animals.
RESULTS
The bolus dose of L-687,4 14 of 17. 6 mg/kg gave an estimated peak plasma level of 24 fl-g/ml plasma that decayed with a 11/2 of 56 min (Fig. 1 ). The three infusion regimens (7 mg/kg i. v. bolus + 7 mg/kg/h for 4 h; 14 mg/kg + 14 mg/kg/h for 4 h; 30 mg/kg + 30 mg/kg/h for 4 h) resulted in average plasma levels of 11, 25, and 61 fl-g/ml throughout the 4-h experi mental period (Fig. 1) . The physiological variables for the four doses of L-687,4 14 are shown in Table 1 . There was no sig nificant difference between the control and 17. 6-mg/ kg dose of L-687,414-treated animals for the P aco2 (ANOYA, F = 1. 24, P > 0. 2), Pao2 (ANOYA, F = 0.03, p > 0. 9), blood glucose (ANOYA, F = 0. 84, p > 0. 3), or pH (ANOY A, F = 0. 26, p > 0. 6). The infusion regimen resulting in average plasma levels of 11 fl-g/ml produced no significant difference for the Pao2 (ANOYA, F = 3. 35, p > 0.08), blood glu cose (ANOY A, F = 0. 12, p > 0. 7), or pH (ANOY A, F = 2. 9, P > 0. 1). However, there was an overall significant difference for the P aco2 (ANOY A, F = 4.53, P < 0.05). Comparison of the different time points revealed a significant (p < 0. 05) difference at the 4-h time of measurement. There was no significant difference between the control and 25-fl-g/ml dose of L-687,4 14 for any of the physiological variables: P aco2 (ANOY A, F = 0. 16, P > 0. 7), Pao2 (ANOYA, F = 0. 32, p > 0.6), blood glucose CANOY A, F = 4. 3, p > 0.05), or pH (ANOYA, F = 0. 52, p > 0.4). Finally, there was no significant difference between the control and 61fl-g/ml dose of L-687 ,4 14 for any of the physiological parameters: PaC02 (ANOYA, F = 0.2 1, p > 0. 6), Pao2 (ANOYA, F = 1. 41, p > 0.2), blood glucose (ANOYA, F = 0.45, p > 0. 5), or pH (ANOYA, F = 2. 93, p > 0. 09). The body and temporalis muscle temperature had also been strictly maintained at 37 ± 0. 8°C.
Permanent occlusion of the left MCA with 4-h survival resulted in neuronal degeneration in the dorsolateral cortex and the caudate nucleus. The cells within the boundary of the lesion showed clas sic ischaemic changes with a shrunken cytoplasm and triangular and pyknotic nucleus that was darkly stained. The lesion boundary was quite easily iden tified in sections that had been stained with haema toxylin-eosin. For the volumetric analysis, eight sections at predetermined stereotactic levels of -10.5 to -1.02 mm were used (Osborne et aI., 1987) .
The 17. 6-mg/kg i. v. bolus dose ofL-687,414 gave no significant protection against the volume of isch aemic damage for the hemisphere (ANOY A, F = 1.82, p > 0. 2), cortex (ANOY A, F = 1.66, p > 0. 2), or caudate (ANOY A, F = 0. 45, p > 0.5) compared with the control group of animals ( Fig. 2A) . The area of cortical damage at the different stereotactic levels is illustrated in Fig. 2B . There was no signif icant difference between the control and L-687,4 14treated groups at any of the levels studied (BMDP 2v, ANOYA, F = 1.75, p > 0. 2).
In the second experiment an intravenous bolus dose of 7 mg/kg was followed by an infusion of 7 mg/kg/h for 4 h, which resulted in a mean plasma level of 11 fLg/ml (Fig. 1 ). There was no significant difference for the volume of hemispheric (ANaYA, F = 0.48, p > 0.5), cortical (ANaYA, F = 3.22, p > 0.08), or caudate (ANOY A, F = 1.2 1, p > 0.2) damage between the control and L-687,4 14 groups of animals (Fig. 3A) . The area of ischaemic damage for this dose of L-687 ,4 14 at the different stereotac tic levels is shown in Fig. 4A , and again there was no overall significant difference between the two groups of animals (BMDP 2v, ANOY A, F = 3.6 1, p > 0.07). The volume of damage for the middle dose of L-687,414, which gave a plasma level of 25 f-Lg/ml, is shown in Fig. 3B . There was a highly significant protective effect against the volume of hemispheric (ANaYA, F = 31.55, p < 0.000 1) and cortical (ANaYA, F = 30.34, p < 0.0001) damage for the L-687,414-treated animals compared with the con trol group. There was no significant difference seen for the volume of caudate damage (ANOYA, F = 0.23, p > 0.6; Fig. 3B ) between the two groups of animals. A comparison between the groups for the area of cortical damage at the different stereotactic levels revealed that there was an overall significant difference (BMDP 2v, ANOY A, F = 31.32, p < 0.0001). A contrast test was done to test signifi cance at each of the stereotactic levels. This showed there was, in fact, a significant difference at each level from anterior 10.5 mm to anterior 1.02 mm (Fig. 4B ). The area of cortical damage was sig nificantly less in the L-687,4 14-treated animals at each stereotactic level. The highest dosing regimen of L-687,4 14 tested gave an average plasma level of 60.8 f-Lg/ml over the 4-h period (Fig. 1) . This dose of L-687,414 resulted in significant protection against the volume of hemi spheric (ANaYA, F = 10.9, p < 0.0 1) and cortical (ANOYA, F = 9.45, p < 0.0 1) ischaemic damage when compared with the control group, but no sig nificant protection was seen against caudate dam age (ANaYA, F = 2.26, p > 0. 1; Fig. 3C ). There was also an overall significant (ANaYA, F = 9.70,
<J)
Ol ro Each bar represents the mean ± SD of 10 animals. B: A com parison was done of the area of ischaemic damage in the cerebral cortex at the different stereotactic levels for the sa line controls (filled squares) and L-687,414, 17.6 mg/kg i.v.
treated animals (open circles). There was no significant re duction in the area of cortical damage at any of the coronal levels using this dosing regimen. Each point represents the mean ± SD of 10 animals. p < 0,01) difference between the control and L-687,414-treated animals for the area of cortical damage at the different stereotactic levels. A con trast test for each stereotactic level revealed a sig nificant difference at stereotactic levels of anterior 8.92 mm and anterior 6.06 mm to 2.18 mm (Fig. 4C) . The magnitude of protection was less with this dose than seen with the middle dose. The effects of the 17.6 mg/kg dose of L-687,4 14 on MABP are shown in Fig. 5 , There was no overall significant difference between the control group and the L-687,4 14-treated group of animals (BMDP 2v, ANOV A, F = 1.3, p > 0.2). The MABPs for the three infusion dosing regimes of L-687,4 14 are shown in Fig. 6 . There was no overall significant effect of L-687 ,414 on the MABP at any of the doses used, with plasma levels of 11 J-Lg/ml (BMDP 2v, ANOV A, F = 0.97, P > 0.3), 25 J-Lg/ml (BMDP 2v, ANOVA, F = 2.93, p > 0. 1), and 61 J-Lg/ml (BMDP 2v, ANOVA, F = 0.72, p > 0.4). However, when a comparison between control and L-687,4I4 animals was done for each time point at which MABP was measured, there was a significant difference at 15 min post MCA occlusion for the 25-J-Lg/ml plasma level dosing regimen (Fig. 6B) . The high dosing reg- The low dose (7 mg/kg + 7 mg/kg/h for 4 h) of L-687,414 that gave a plasma level of 11 J.Lg/ml gave no significant reduction of the area of cortical damage at the different coronal levels when compared with its controls. B: The area of ischaemic damage for the 25-J.L91 ml dosing regimen (14 mg/kg + 14 mg/kg/h for 4 h) was significantly (p < 0.0001) less than that in the control group. There was a significant reduction (*p < 0.05; **p < 0.01) in the ischaemic area at each stereotactic level. C: The highest plasma level of L-687,414, 60,8 J.Lg/ml (30 mg/kg + 30 mgl kg/h for 4 h), also produced a significant (p < 0.01) decrease in the overall area of cortical damage, and there was a sig nificant difference (*p < 0.05; **p < 0.01) at most of the in dividual coronal levels. Each point represents the mean ± SD for n = 11-16 animals.
imen, giving a plasma level of 61 f-Lg/ml, resulted in a significant decrease in MABP at 15 and 30 min post MCA occlusion (Fig. 6C) . The MABP was re duced by 13 and 16 mm Hg, respectively, at these two time points.
DISCUSSION
These studies were conducted to investigate the dose-effect relationship of a glycine site antagonist in a model of focal ischaemia. The acute focal isch aemia model was used to enable continuous moni-J Cereb Blood Flow Metab, Vol. 15, No.2, 1995 to ring of the physiological variables such as MABP, Paco2, Pao2, pH, blood glucose, and temperature throughout the study. Furthermore, repeated blood samples were available, enabling close monitoring of L-687,414 plasma levels over the 4-h duration of the experiment.
L-687,414 gave a significant protective effect when average plasma levels of 25 and 61 f-Lg/ml were maintained throughout the 4-h experimental period. These doses resulted in 34 and 18% protection against the volume of hemispheric damage and 41 and 22% protection against cortical damage, respec tively. The reduced neuroprotective effect seen with the higher dose may be due to the slight (13-16 mm Hg) but significant decrease in MABP seen at 15 and 30 min after drug administration had been started. This effect on blood pressure may have been due to the interaction with halothane, which has also been reported for MK-801 (Kurumaji and McCulloch, 1989) . A hypotensive phase of this magnitude is enough to increase the size of infarct in this model of permanent MCA occlusion (Os borne et aI., 1987; Dirnagl and Pulsinelli, 1990) . In contrast to this effect in anaesthetised rats, similar doses of L-687,414 had no effect on MABP, heart rate, or respiration in conscious animals (Har greaves et aI., 1993a) .
Thus, with this glycine site antagonist, a bell shaped dose-response curve was obtained similar to that seen with ion channel-blocking drugs (Gill et aI., 1991a; Bielenberg and Beck, 1991) and compet itive NMDA antagonists (Park et aI., 1992) . There was no protection seen against caudate nucleus damage with the doses that protected against hemi spheric and cortical damage. The reason for this is that the lenticulostriate branch is occluded in this model, and this is the main blood supply to the cau date nucleus.
A possible criticism of the present study is that the animals were allowed to survive for a period of only 4 h after MCA occlusion and that there may be further progression of infarct volume up to 24 h. However, Park (1988) has demonstrated that the size of infarct seen at 4 and 24 h after permanent MCA occlusion is the same and furthermore that the extent of protection afforded by the ion channel blocker MK-801 was the same when assessed at 4 or 24 h after MCA occlusion. Kaplan et al. (1991) have also demonstrated that the infarct size is al most maximal around 3-4 h after permanent MCA occlusion. Thus, by analogy with the MK-801 data, it seems unlikely that L-687,414 is merely delaying ischaemic damage, but it is actually protecting against the ischaemia-induced neuronal damage.
The glycine site on the NMDA receptor complex offers an alternative site for targeting potential neu roprotective agents. The advantages of L-687,414 acting at this site may be related to its partial ago nist properties such that it prevents the overactiva tion of NMDA receptors during ischaemia, which leads to neurodegeneration, whilst still permitting some NMDA transmission in nonischemic tissue to proceed.
The optimum neuroprotective dosing regimen of L-687,414, which gave a steady-state plasma level of 25 fl-g/ml, and the higher dosing regimen have also been tested for their effects on glucose utilisa tion. These doses of L-687 ,414 gave no increases in glucose utilisation in any of the brain regions exam ined (Hargreaves et al., 1993a) . Furthermore, these same doses of L-687,414 did not produce neuronal vacuolisation in the posterior cingulate cortex, un like MK-801 and competitive NMDA antagonists (Hargreaves et al., 1993a,b) . Therefore, in these re spects, antagonism of the NMDA receptor at the glycine site by L-687 ,414 may be advantageous over antagonism of the ion channel (MK-801) and gluta mate transmitter recognition sites that are associ ated with glucose hypermetabolism and neuronal vacuolisation (McCulloch and Iversen, 1991) . The neuronal vacuolisation produced by the competitive and uncompetitive NMDA antagonists is thought to be a consequence of the increases in glucose utili sation seen with these compounds (McCulloch, 1991) .
The other advantages ofL-687.414 as a neuropro tective agent are that this compound has an im proved behavioural profile over ion channel blocking NMDA antagonists. L-687 ,414 was shown to produce ataxia only at a dose of >44 mg/kg i. v., and this was five times higher than the anticonvul sant dose (Saywell et al., 1991) . L-687,414 has also been reported to antagonise photically induced my oclonus in baboons in a dose-dependent manner (5-45 mg/kg i.v.), and this was not associated with any untoward behavioural effects (Smith and Meldrum, 1992) .
In conclusion, while glycine site antagonism by L-687,414 produces neuroprotective and anticon vulsant effects it has a much reduced propensity to produce the adverse side effects of ion channel blockers that have compromised their clinical de velopment to date.
